ArticleMicrobial cell factories2026
Heterotrophic fermentation of a robust human defensin in Chlamydomonas reinhardtii provides a stable and potent antibacterial.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms and Production of Hypoglycaemic Peptides: Exploring the Potential ofFood science & nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe growing threat of antibiotic resistance underscores the urgent need for novel therapeutic agents. Antimicrobial peptides (AMPs), such as human defensins, are promising candidates due to their broad-spectrum activities, but their widespread application is severely hindered by high production costs and limited stability. Among these, human neutrophil peptide-2 (HNP2), a member of the α-defensin family, is a particularly potent AMP that kills microorganisms by disrupting their membrane integrity. The eukaryotic microalga Chlamydomonas reinhardtii (C. reinhardtii) has emerged as a low-cost and efficient bioreactor for exogenous protein production, yet its potential for expressing human defensins remains largely unexplored. This study aimed to express a tandem trimer of the HNP2 mature peptide (3×HNP2) in C. reinhardtii and to characterize its stability, safety, and antibacterial functions.
resultsIn this study, a gene encoding 3×HNP2 was successfully expressed in the C. reinhardtii strain CC-5325, yielding a fusion protein of approximately 22 kDa. The recombinant protein's expression remained stable for over five months of continuous subculturing. Obtained via fermentation technology and affinity purification, the purified 3×HNP2 demonstrated potent antibacterial activity against the Gram-negative pathogens Pseudomonas aeruginosa (P. aeruginosa) and Escherichia coli (E. coli). The protein exhibited high thermal stability (up to 90 °C), broad pH tolerance (pH 2-10), and resistance to degradation by proteinase K and papain. Mechanistic investigations using propidium iodide (PI) staining and scanning electron microscopy (SEM) confirmed that 3×HNP2 acts by disrupting bacterial membrane integrity. Furthermore, qRT-PCR analysis revealed that 3×HNP2 significantly downregulated the expression of key virulence-associated genes (lecA, phzA2, csgA, and rpoS). Biosafety assays showed that the peptide had minimal hemolytic activity and low cytotoxicity against mammalian cell lines.
conclusionsThis work establishes a green platform for producing a functional human defensin in C. reinhardtii. It demonstrates that algae-derived 3×HNP2 is a stable, safe, and effective antimicrobial agent, suggesting its potential as a candidate for further development in antimicrobial therapeutics or food safety applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.